Empower Clinic Services, LLC dba Empower Pharmacy

Has Empower Clinic Services, LLC dba Empower Pharmacy received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Empower Clinic Services, LLC dba Empower Pharmacy a warning letter naming semaglutide and tirzepatide, dated Sep 18, 2026, with the FDA subject line “CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug.”

FDA records in this index name Empower Clinic Services, LLC dba Empower Pharmacy on Sep 18, 2026.

Type named in FDA records
Not stated
FDA warning letters
1
Drug recall reports
0
Drugs named
Semaglutide, Tirzepatide
Latest record
Sep 18, 2026

FDA warning letters

Later letters FDA listsLetter
Sep 18, 2026CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

No openFDA drug recall reports in this index.

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 facilities under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503B)

9 listed actions, including 4 Form 483s, 2 warning letters and 1 untitled letter (2019 to 2025).

Document
Nov 14, 2025Form 483483 Issued 11/14/2025fda.gov
Apr 2, 2025Warning letterWarning Letter Issued 04/02/2025FDA copy (archived)
Aug 28, 2024Form 483483 Issued 08/28/2024FDA copy (archived)
May 4, 2023Regulatory meetingRegulatory Meeting Held 05/04/2023Not linked by FDA
Aug 5, 2022Form 483483 Issued 08/05/2022FDA copy (archived)
Oct 15, 2021Warning letterWarning Letter (10/15/2021)FDA copy (archived)
Mar 6, 2020Form 483483 Issued 03/06/2020FDA copy (archived)
Jul 22, 2019Untitled letterUntitled Letter Issued 07/22/2019FDA copy (archived)
Apr 2, 2019FMD-145 letterFMD-145 Letter Issued 04/02/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Empower Clinic Services, LLC, (dba Empower Pharmacy), Houston, TX (503A)

5 listed actions, including 3 Form 483s and 2 warning letters (2023 to 2026).

Document
Sep 18, 2026Warning letterWarning Letter Issued 09/18/2026fda.gov
Nov 14, 2025Form 483483 Issued 11/14/2025fda.gov
Apr 2, 2025Warning letterWarning Letter Issued 04/02/2025fda.gov
Oct 4, 2024Form 483483 Issued 10/04/2024FDA copy (archived)
Dec 1, 2023Form 483483 Issued 12/01/2023FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Empower Pharmacy (Empower Clinic Services, LLC), Houston, TX.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.